The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 30, No. 12, pp. 1437-1445.
© 1996 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fischer,
Right arrow Articles by Baer, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fischer, , JR
Right arrow Articles by Baer, R.


Research Articles

Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents

Fischer JR and RK Baer

OBJECTIVE: To review the occurrence and pathophysiology of myopathy associated with combined use of neuromuscular blocking agents (NMBAs) and systemic corticosteroids. DATA SOURCES: A MEDLINE search (1985 to July 1995, English language) yielded case reports and clinical studies involving myopathy or weakness associated with the use of NMBAs and/or corticosteroids. References cited in those articles were reviewed. DATA SYNTHESIS: Prolonged muscle weakness has been reported in intubated patients in the intensive care unit (ICU) who were receiving NMBAs and/or corticosteroids. Many cases involved the use of both agents in individuals with no underlying risk factors. The term "blocking agent-corticosteroid myopathy" (BACM) has been used to describe this myopathy when it develops following combined use of these agents. Features common to BACM include prolonged weakness, elevated creatine kinase concentrations, myopathic features on electromyography, normal nerve conduction and sensation, and reduced deep tendon reflexes. Muscle biopsy results vary, but tend to show type 1 and/or 2 fiber atrophy without inflammation. Some recently reported cases revealed thick myosin myofilament loss, which is consistent with findings in denervated rat muscle after exposure to corticosteroids. Two small prospective studies reported that 36-50% of mechanically ventilated patients receiving either one or both drugs developed prolonged weakness. CONCLUSIONS: NMBAs and corticosteroids alone have both been reported to cause myopathy in patients in the ICU. When coadministered, these agents appear to confer an even greater risk of myopathy; the exact pathology is not understood. Concomitant use of NMBAs and corticosteroids should be avoided if possible. Guidelines for cautious use and careful monitoring are suggested when combined use is deemed necessary.


This article has been cited by other articles:


Home page
Br J AnaesthHome page
S. Soltesz, T. Mencke, C. Mey, S. Rohrig, C. Diefenbach, and G. P. Molter
Influence of a continuous prednisolone medication on the time course of neuromuscular block of atracurium in patients with chronic inflammatory bowel disease
Br. J. Anaesth., June 1, 2008; 100(6): 798 - 802.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. N. Sessler
Train-of-Four To Monitor Neuromuscular Blockade?
Chest, October 1, 2004; 126(4): 1018 - 1022.
[Full Text] [PDF]


Home page
Br J AnaesthHome page
T. M. Cook, R. T. Protheroe, and J. M. Handel
Tetanus: a review of the literature
Br. J. Anaesth., September 1, 2001; 87(3): 477 - 487.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. A. JANTZ and S. A. SAHN
Corticosteroids in Acute Respiratory Failure
Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1079 - 1100.
[Full Text]




homecopy help contact us subscription past issues search current issue
Copyright © 1996 by Harvey Whitney Books Company.